AnHeart Therapeutics

About:

AnHeart Therapeutics is a developer of innovative pharmaceutical products.

Website: http://anhearttherapeutics.com/en/home

Top Investors: Innovent Biologics, Vertex Ventures China, Decheng Capital, Laurion Capital Management, Octagon Capital Advisors

Description:

AnHeart Therapeutics is a developer of innovative pharmaceutical products. The company is focused on acquiring, developing and commercializing innovative pharmaceutical products that improve human health and quality of life. It's main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.

Total Funding Amount:

$75.6M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Hangzhou, Zhejiang, China

Founded Date:

2018-01-01

Contact Email:

BD(AT)anhearttherapeutics.com

Founders:

Junyuan (Jerry) Wang, Lihua Zheng

Number of Employees:

51-100

Last Funding Date:

2021-12-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai